Clinical Trials Directory

Trials / Unknown

UnknownNCT05563064

Effect of Herbal Formulation on Thrombocytes Count

Effect of Herbal Formulation on Karika Syrup on Thrombocytes Count

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Shifa Ul Mulk Memorial Hospital · Academic / Other
Sex
All
Age
14 Years – 60 Years
Healthy volunteers
Accepted

Summary

Effect of Herbal Formulation Karika Syrup on Thrombocyte Count.

Detailed description

In this study, we will evaluate the effect of Herbal Formulation Karika (composed of Carica papaya leaf extract and Tinosporacordifolia) on Complete Blood Count, specifically on Platelet Count. Low Platelet Count is highly observant during multiple diseases namely dengue, malaria, typhoid, chikungunya, viral infections, and other Diseases. The proposed study is a randomized, open, prospective, multicenter clinical trial. Extracts found in Karika syrup are beneficial in escalating platelet count, and also have anti-inflammatory and antipyretic activity. The therapeutic indication of Karika is proven through this clinical study in patients with low platelet count associated with dengue, typhoid, malaria, viral fever, and chikungunya fever. Dengue is a tropical disease caused by the RNA virus which resides in mosquitoes. Symptoms include high-grade fever, visual disturbances, pain in the eyes and head, nausea, vomiting, musculoskeletal pain, stiffness of joints, mild to moderate and severe bleeding, and sometimes puerperal rash appearing on the skin due to a deficiency of thrombocytes. The Chikungunya virus is spread by the bite of an infected mosquito. Typhoid is caused by Salmonella typhi a bacterium. Typhoid fever symptoms are seen widely in the human body that may observe from relatively minor cases of diarrhea with low-grade fever to high-grade fever and profound diarrhea with involvement of multiple systems.1

Conditions

Interventions

TypeNameDescription
DRUGKarika SyrupTo evaluate the effects of Karika syrup on complete blood count specifically thrombocytes (platelets) collected from blood samples of patients after treatment of 15 days long period.

Timeline

Start date
2021-01-01
Primary completion
2023-01-01
Completion
2023-01-01
First posted
2022-10-03
Last updated
2022-10-04

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT05563064. Inclusion in this directory is not an endorsement.